Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PARVEZ S MANTRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1770528697
CMS profile
80276
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$206,568.87

167 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PARVEZ S MANTRY

NPI 1770528697 · CMS profile ID 80276

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770528697?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770528697?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770528697?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PARVEZ S MANTRY, NPI 1770528697, CMS profile ID 80276, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1770528697?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

167 matching records · $206,568.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 167 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–167 of 167.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $28.0202/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961476 CMS
Gilead Sciences, Inc. $3,940.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133605732 CMS
ABBVIE INC. $19.0302/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961474 CMS
Gilead Sciences, Inc. $23.3202/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133786201 CMS
Gilead Sciences, Inc. $109.4102/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133786199 CMS
Gilead Sciences, Inc. $762.1302/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133865326 CMS
Genentech USA, Inc. $682.8802/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133085188 CMS
Genentech USA, Inc. $138.6402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133085192 CMS
Genentech USA, Inc. $171.0402/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133085196 CMS
Genentech USA, Inc. $537.8402/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133085200 CMS
ABBVIE INC. $2,625.0001/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961472 CMS
ABBVIE INC. $19.6301/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961468 CMS
ABBVIE INC. $124.4001/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961470 CMS
ABBVIE INC. $22.5801/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104961466 CMS
Boston Scientific Corporation $32.2601/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092602688 CMS
Gilead Sciences, Inc. $24.4301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133786197 CMS
Novo Nordisk Inc $4,650.0001/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097545021 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $122,609.74 174
PY2020 $51,008.89 76
PY2021 $73,394.30 131
PY2022 $105,760.77 123
PY2023 $96,639.08 120
PY2024 $206,568.87 167
PY2025 $302,443.12 261

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $569,293.58 261
PY2024 Principal investigator $560,095.99 270
PY2023 Principal investigator $611,008.07 164
PY2022 Principal investigator $275,708.61 76
PY2021 Principal investigator $524,314.75 357
PY2020 Principal investigator $1,871,030.58 259
PY2019 Principal investigator $996,131.00 217

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

261 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,700.00 12/24/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171330
Principal investigator 1 Genentech, Inc. $1,100.00 12/19/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625086
Principal investigator 1 Genentech, Inc. $600.00 12/19/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625100
Principal investigator 1 Genentech, Inc. $570.00 12/19/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625114
Principal investigator 1 Ipsen Bioscience Inc. $95.00 12/19/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546351
Principal investigator 1 Ipsen Bioscience Inc. $75.00 12/19/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,786.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $252.20 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 12/19/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131620
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,924.00 12/18/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171310
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,470.00 12/11/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171242
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,331.57 12/11/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171306
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 12/04/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,353.00 12/04/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131602
Principal investigator 1 Genentech, Inc. $75.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625090
Principal investigator 1 Genentech, Inc. $2,833.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625094
Principal investigator 1 Genentech, Inc. $570.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625096
Principal investigator 1 Genentech, Inc. $2,175.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625105
Principal investigator 1 Genentech, Inc. $11,784.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625109
Principal investigator 1 Genentech, Inc. $95.00 12/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625118
Principal investigator 1 Ipsen Bioscience Inc. $1,067.00 11/25/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546349
Principal investigator 1 Ipsen Bioscience Inc. $6,660.36 11/20/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546347
Principal investigator 1 Ipsen Bioscience Inc. $1,000.00 11/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546343
Principal investigator 1 Ipsen Bioscience Inc. $500.00 11/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 11/14/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131600
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 11/13/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171240
Principal investigator 1 Intercept Pharmaceuticals, Inc. $453.50 11/13/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171300
Principal investigator 1 Intercept Pharmaceuticals, Inc. $928.50 11/13/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171304
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 11/13/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211415311
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 11/07/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,353.00 11/07/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 11/07/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.50 11/07/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131598
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,951.00 11/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171302
Principal investigator 1 Genentech, Inc. $2,833.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625063
Principal investigator 1 Genentech, Inc. $75.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625067
Principal investigator 1 Genentech, Inc. $95.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625071
Principal investigator 1 Genentech, Inc. $75.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625075
Principal investigator 1 Genentech, Inc. $2,833.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625079
Principal investigator 1 Genentech, Inc. $95.00 11/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625084
Principal investigator 1 Sirtex Medical Inc $1,000.00 11/01/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918519
Principal investigator 1 Ipsen Bioscience Inc. $75.00 10/29/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546339
Principal investigator 1 Ipsen Bioscience Inc. $95.00 10/29/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546341
Principal investigator 1 Genentech, Inc. $33,149.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624997
Principal investigator 1 Genentech, Inc. $95.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625007
Principal investigator 1 Genentech, Inc. $75.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625011
Principal investigator 1 Genentech, Inc. $570.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625022
Principal investigator 1 Genentech, Inc. $4,675.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625045
Principal investigator 1 Genentech, Inc. $11,784.00 10/22/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625054
Principal investigator 1 Genentech, Inc. $95.00 10/17/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624981
Principal investigator 1 Genentech, Inc. $75.00 10/17/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625003
Principal investigator 1 Genentech, Inc. $2,559.00 10/17/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625058
Principal investigator 1 Ipsen Bioscience Inc. $95.00 10/16/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546333
Principal investigator 1 Ipsen Bioscience Inc. $98.00 10/16/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546335
Principal investigator 1 Ipsen Bioscience Inc. $75.00 10/16/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,043.00 10/16/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $514.80 10/16/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131592
Principal investigator 1 Intercept Pharmaceuticals, Inc. $453.50 10/14/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171298
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,053.50 10/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171296
Principal investigator 1 Genentech, Inc. $75.00 10/08/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624995
Principal investigator 1 Genentech, Inc. $2,833.00 10/08/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625029
Principal investigator 1 Genentech, Inc. $95.00 10/08/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625037
Principal investigator 1 Genentech, Inc. $75.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624986
Principal investigator 1 Genentech, Inc. $570.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624991
Principal investigator 1 Genentech, Inc. $95.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625000
Principal investigator 1 Genentech, Inc. $95.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625013
Principal investigator 1 Genentech, Inc. $570.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625018
Principal investigator 1 Genentech, Inc. $2,833.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625025
Principal investigator 1 Genentech, Inc. $75.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625033
Principal investigator 1 Genentech, Inc. $2,833.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625041
Principal investigator 1 Genentech, Inc. $570.00 10/01/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211625050
Principal investigator 1 Ipsen Bioscience Inc. $414.96 09/23/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,830.00 09/23/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $804.30 09/23/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,772.70 09/23/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131588
Principal investigator 1 Genentech, Inc. $6,660.00 09/19/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624944
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,498.50 09/18/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171288
Principal investigator 1 Intercept Pharmaceuticals, Inc. $508.00 09/18/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171292
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,331.57 09/18/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171294
Principal investigator 1 Ipsen Bioscience Inc. $600.00 09/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546325
Principal investigator 1 Ipsen Bioscience Inc. $500.00 09/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546327
Principal investigator 1 Ipsen Bioscience Inc. $500.00 09/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.50 09/18/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 09/18/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131582
Principal investigator 1 Bausch Health US, LLC $1,670.00 09/11/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843364
Principal investigator 1 Intercept Pharmaceuticals, Inc. $10,834.20 09/11/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171290
Principal investigator 1 Genentech, Inc. $570.00 09/10/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624927
Principal investigator 1 Genentech, Inc. $18,163.00 09/10/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624948
Principal investigator 1 Genentech, Inc. $570.00 09/10/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624963
Principal investigator 1 Ipsen Bioscience Inc. $1,920.00 09/04/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546323
Principal investigator 1 TAIHO ONCOLOGY, INC. $493.70 09/04/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416054
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 08/22/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171312
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 08/19/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171238
Principal investigator 1 Ipsen Bioscience Inc. $1,025.05 08/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546315
Principal investigator 1 Ipsen Bioscience Inc. $500.00 08/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546317
Principal investigator 1 Ipsen Bioscience Inc. $500.00 08/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546319
Principal investigator 1 Ipsen Bioscience Inc. $500.00 08/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546321
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 08/13/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211419581
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,719.60 08/12/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211418847
Principal investigator 1 Bausch Health US, LLC $340.00 08/08/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843368
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 08/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171286
Principal investigator 1 TAIHO ONCOLOGY, INC. $493.70 08/06/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416046
Principal investigator 1 Sirtex Medical Inc $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.50 07/31/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131578
Principal investigator 1 TAIHO ONCOLOGY, INC. $170.00 07/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211418843
Principal investigator 1 Genentech, Inc. $570.00 07/18/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624937
Principal investigator 1 TAIHO ONCOLOGY, INC. $325.85 07/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416738
Principal investigator 1 TAIHO ONCOLOGY, INC. $21,788.91 07/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211418845
Principal investigator 1 TAIHO ONCOLOGY, INC. $22,366.91 07/18/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211419579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 07/04/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 07/04/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 07/04/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131576
Principal investigator 1 Genentech, Inc. $4,335.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624924
Principal investigator 1 Genentech, Inc. $2,833.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624931
Principal investigator 1 Genentech, Inc. $4,341.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624934
Principal investigator 1 Genentech, Inc. $95.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624940
Principal investigator 1 Genentech, Inc. $95.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624950
Principal investigator 1 Genentech, Inc. $600.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624954
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624959
Principal investigator 1 Genentech, Inc. $11,784.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624967
Principal investigator 1 Genentech, Inc. $1,000.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624972
Principal investigator 1 Genentech, Inc. $75.00 07/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624976
Principal investigator 1 Ipsen Bioscience Inc. $414.96 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546275
Principal investigator 1 Ipsen Bioscience Inc. $2,057.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546277
Principal investigator 1 Ipsen Bioscience Inc. $98.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546279
Principal investigator 1 Ipsen Bioscience Inc. $95.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546281
Principal investigator 1 Ipsen Bioscience Inc. $75.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546283
Principal investigator 1 Ipsen Bioscience Inc. $95.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546285
Principal investigator 1 Ipsen Bioscience Inc. $98.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546287
Principal investigator 1 Ipsen Bioscience Inc. $75.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546289
Principal investigator 1 Ipsen Bioscience Inc. $500.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546291
Principal investigator 1 Ipsen Bioscience Inc. $500.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546293
Principal investigator 1 Ipsen Bioscience Inc. $600.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546295
Principal investigator 1 Ipsen Bioscience Inc. $500.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546297
Principal investigator 1 Ipsen Bioscience Inc. $500.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546299
Principal investigator 1 Ipsen Bioscience Inc. $600.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546301
Principal investigator 1 Ipsen Bioscience Inc. $150.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546303
Principal investigator 1 Ipsen Bioscience Inc. $193.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546305
Principal investigator 1 Ipsen Bioscience Inc. $75.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546307
Principal investigator 1 Ipsen Bioscience Inc. $75.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546309
Principal investigator 1 Ipsen Bioscience Inc. $95.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546311
Principal investigator 1 Ipsen Bioscience Inc. $98.00 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,752.00 06/24/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.00 06/24/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 06/24/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 06/24/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131570
Principal investigator 1 TAIHO ONCOLOGY, INC. $378.35 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211418849
Principal investigator 1 TAIHO ONCOLOGY, INC. $402.45 06/24/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211419585
Principal investigator 1 TAIHO ONCOLOGY, INC. $11,857.66 06/19/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211415317
Principal investigator 1 Ipsen Bioscience Inc. $1,035.00 06/12/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546269
Principal investigator 1 Ipsen Bioscience Inc. $95.00 06/12/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546271
Principal investigator 1 Ipsen Bioscience Inc. $75.00 06/12/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,782.00 06/12/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,000.00 06/12/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 06/12/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,184.00 06/12/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 06/12/2025 Covered Recipient Teaching Hospital
METHODIST DALLAS MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184131562
Principal investigator 1 Genentech, Inc. $665.00 06/11/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624896
Principal investigator 1 Genentech, Inc. $150.00 06/11/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624902
Principal investigator 1 Bausch Health US, LLC $1,255.41 06/05/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843378
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,293.73 06/05/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211417423
Principal investigator 1 Genentech, Inc. $570.00 06/04/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624891
Principal investigator 1 Genentech, Inc. $11,784.00 05/28/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624899
Principal investigator 1 Genentech, Inc. $14,730.00 05/28/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624912
Principal investigator 1 TAIHO ONCOLOGY, INC. $21,788.91 05/28/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211419583
Principal investigator 1 Ipsen Bioscience Inc. $4,917.77 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546259
Principal investigator 1 Ipsen Bioscience Inc. $3,200.00 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546261
Principal investigator 1 Ipsen Bioscience Inc. $75.00 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546263
Principal investigator 1 Ipsen Bioscience Inc. $95.00 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546265
Principal investigator 1 Ipsen Bioscience Inc. $98.00 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546267
Principal investigator 1 TAIHO ONCOLOGY, INC. $325.85 05/22/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416050
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 05/16/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171324
Principal investigator 1 Intercept Pharmaceuticals, Inc. $175.00 05/16/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171326
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 05/15/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171282
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,217.50 05/15/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171284
Principal investigator 1 Bausch Health US, LLC $1,564.90 05/13/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843382
Principal investigator 1 Ipsen Bioscience Inc. $500.00 05/08/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546253
Principal investigator 1 Ipsen Bioscience Inc. $500.00 05/08/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546255
Principal investigator 1 Ipsen Bioscience Inc. $500.00 05/08/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546257
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 05/08/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416052
Principal investigator 1 Ipsen Bioscience Inc. $1,784.00 04/28/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546249
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,470.00 04/23/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171322
Principal investigator 1 Ipsen Bioscience Inc. $5,231.00 04/23/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176546251
Principal investigator 1 Sirtex Medical Inc $1,500.00 04/15/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918515
Principal investigator 1 Intercept Pharmaceuticals, Inc. $221.00 04/10/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171274
Principal investigator 1 Intercept Pharmaceuticals, Inc. $453.50 04/10/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171276
Principal investigator 1 Intercept Pharmaceuticals, Inc. $928.50 04/10/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171278
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,269.50 04/10/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171280
Principal investigator 1 Genentech, Inc. $75.00 04/09/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624907
Principal investigator 1 Genentech, Inc. $2,833.00 04/09/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624917
Principal investigator 1 Genentech, Inc. $95.00 04/09/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624920
Principal investigator 1 Bausch Health US, LLC $1,648.40 04/07/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843388
Principal investigator 1 TAIHO ONCOLOGY, INC. $378.35 04/04/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211420311
Principal investigator 1 Bausch Health US, LLC $1,500.00 04/01/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843391
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,648.00 03/21/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171320
Principal investigator 1 TAIHO ONCOLOGY, INC. $378.35 03/20/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211415315
Principal investigator 1 TAIHO ONCOLOGY, INC. $378.35 03/20/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416048
Principal investigator 1 Genentech, Inc. $11,784.00 03/19/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624864
Principal investigator 1 Ipsen Bioscience Inc. $414.96 03/19/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546247
Principal investigator 1 Sirtex Medical Inc $125.00 03/17/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918511
Principal investigator 1 Sirtex Medical Inc $125.00 03/17/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918513
Principal investigator 1 Ipsen Bioscience Inc. $225.00 03/11/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546243
Principal investigator 1 Ipsen Bioscience Inc. $75.00 03/11/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546245
Principal investigator 1 Bausch Health US, LLC $1,946.23 03/05/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843371
Principal investigator 1 Ipsen Bioscience Inc. $4,579.18 03/04/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546241
Principal investigator 1 Intercept Pharmaceuticals, Inc. $928.50 02/27/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171256
Principal investigator 1 Intercept Pharmaceuticals, Inc. $232.50 02/27/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171266
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,899.00 02/27/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171268
Principal investigator 1 Genentech, Inc. $600.00 02/26/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624834
Principal investigator 1 Genentech, Inc. $75.00 02/26/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624838
Principal investigator 1 Genentech, Inc. $95.00 02/26/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624850
Principal investigator 1 Genentech, Inc. $1,727.00 02/26/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624869
Principal investigator 1 Intercept Pharmaceuticals, Inc. $125.00 02/26/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171314
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,105.00 02/26/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171316
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 02/26/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM CLINICAL
Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC No dispute reported 06/30/2026 1248171318
Principal investigator 1 Genentech, Inc. $1,000.00 02/25/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624888
Principal investigator 1 Intercept Pharmaceuticals, Inc. $170.00 02/20/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171232
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,105.00 02/20/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171234
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,033.20 02/20/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171236
Principal investigator 1 TAIHO ONCOLOGY, INC. $526.15 02/20/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211415313
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 02/20/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211420309
Principal investigator 1 TAIHO ONCOLOGY, INC. $15,914.96 02/13/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416044
Principal investigator 1 Genentech, Inc. $570.00 02/07/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624854
Principal investigator 1 Genentech, Inc. $75.00 02/07/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624857
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171230
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,600.00 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171258
Principal investigator 1 Intercept Pharmaceuticals, Inc. $578.50 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171260
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,053.50 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171262
Principal investigator 1 Intercept Pharmaceuticals, Inc. $928.50 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171264
Principal investigator 1 Intercept Pharmaceuticals, Inc. $170.00 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171270
Principal investigator 1 Intercept Pharmaceuticals, Inc. $453.50 02/06/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171272
Principal investigator 1 Genentech, Inc. $14,365.00 02/03/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624841
Principal investigator 1 TAIHO ONCOLOGY, INC. $733.35 01/30/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211416042
Principal investigator 1 TAIHO ONCOLOGY, INC. $14,330.91 01/30/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211417421
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,033.20 01/16/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171226
Principal investigator 1 Intercept Pharmaceuticals, Inc. $170.00 01/16/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171228
Principal investigator 1 Intercept Pharmaceuticals, Inc. $13,895.50 01/16/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171244
Principal investigator 1 TAIHO ONCOLOGY, INC. $325.85 01/16/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements No dispute reported 06/30/2026 1211417419
Principal investigator 1 Genentech, Inc. $12,462.00 01/14/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624861
Principal investigator 1 Sirtex Medical Inc $1,500.00 01/14/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918509
Principal investigator 1 Genentech, Inc. $570.00 01/09/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624847
Principal investigator 1 Genentech, Inc. $75.00 01/09/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624880
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,008.07 01/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171246
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,243.80 01/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171248
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,498.50 01/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171250
Principal investigator 1 Intercept Pharmaceuticals, Inc. $358.50 01/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171252
Principal investigator 1 Intercept Pharmaceuticals, Inc. $453.50 01/09/2025 Non-covered Recipient Entity
METHODIST HEALTH SYSTEM
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171254
Principal investigator 1 Bausch Health US, LLC $6,648.90 01/07/2025 Non-covered Recipient Entity
Methodist Health System Clinical Research Institute
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224843374
Principal investigator 1 Genentech, Inc. $570.00 01/07/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624845
Principal investigator 1 Genentech, Inc. $75.00 01/07/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624874
Principal investigator 1 Ipsen Bioscience Inc. $75.00 01/07/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546237
Principal investigator 1 Ipsen Bioscience Inc. $225.00 01/07/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546239
Principal investigator 1 Sirtex Medical Inc $3,952.00 01/07/2025 Covered Recipient Teaching Hospital
Methodist Dallas Medical Center
DOORwaY Study No dispute reported 06/30/2026 1248918507
Principal investigator 1 Genentech, Inc. $1,000.00 01/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624877
Principal investigator 1 Genentech, Inc. $600.00 01/02/2025 Non-covered Recipient Entity
METHODIST HOSPITALS OF DALLAS METHODIST HEALTH SYSTEM
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211624884